Abstract:Objective: The axis of osteoprotegerin (OPG), the receptor activator for nuclear factor κB (RANK), and RANK ligand (RANKL) has been reported to be critical regulators of skeletal biology and calcification process. However, data was scarce on its involvement in intracranial arterial calcification. Design and method: Hypertensive patients with at least two cardiovascular risk factors were recruited from Shanghai Xinzhuang Community. Plasma OPG (Lifespan, Seattle, WA) and serum RANKL (Biomedica, Vienna, Austria) were measured with commercialized ELISA kits and log-transformed for analysis. Brain tomographic angiography (CTA) was performed with a GE FX/I helical CT scanner (General Electric, United States). The Hounsfield density was measured using a pixel lens on the CTA images. Calcification was defined as a focal high-density lesion of at least 120 Hounsfield units at the intracranial arteries. Pearson's correlation, single and multiple logistic regressions were applied for analysis. Results: The 831 patients (mean age, 65 years; 54% women) included 465 (56%) with intracranial arterial calcification. Mean clinic blood pressure was 137/72 mmHg and 736 (89%) patients were on anti-hypertensive treatment. Plasma OPG, but not serum RANKL, showed seasonal variation (P < 0.001), 15.6% higher (P < 0.001) in summer and 6.0% lower (P < 0.001) in autumn, relative to the mean level in the whole year. Plasma OPG was negatively associated with RANKL (r = −0.25; P < 0.001). The prevalence of intracranial arterial calcification increased with plasma OPG (49.1%, 56.8% and 61.9% in tertiles 1, 2, and 3, respectively; P = 0.003) and decreased with serum RANKL (61.6%, 54.8% and 49.2% in tertiles 1, 2, and 3, respectively; P = 0.005). In continuous analyses, RANKL, but not OPG (P = 0.57), remained significantly associated with intracranial arterial calcification after adjustment (OR [95%CL] associated with 1-SD increase: 0.63 [0.41, 0.99], P = 0.043). RANKL increased by 14.7% with total/HDL cholesterol ratio (P < 0.001), and decreased by 6.9% with neutrophils/lymphocyte ratio (P = 0.02). In pathway analysis, total/HDL cholesterol ratio had both a direct (P = 0.002) and RANKL-mediate indirect (P = 0.008) effect on intracranial arterial calcification. Conclusions: Circulating RANKL was associated with intracranial arterial calcification, highlighting that it might be a marker of intracranial arterial calcification. Further research is warranted to understand the precise mechanisms underpinning this association.

Bone Like Arterial Calcification in Femoral Atherosclerotic Lesions: Prevalence and Role of Osteoprotegerin and Pericytes

Osteal Tissue Macrophages Are Involved in Endplate Osteosclerosis Through the OSM-STAT3/YAP1 Signaling Axis in Modic Changes

The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics

Relationships between Osteopontin, Osteoprotegerin, and Other Extracellular Matrix Proteins in Calcifying Arteries

Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification

Serum biomarkers for arterial calcification in humans: A systematic review

Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification

A1762 Association of Circulating Osteoprotegerin (OPG) and RANKL with Intracranial Arterial Calcification in Hypertensive Patients

Prevalence and progression of arterial calcifications on computed tomography in humans with knee osteoarthritis

Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients

Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis

Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis

Atherosclerosis and Bone Loss in Humans-Results From Deceased Donors and From Patients Submitted to Carotid Endarterectomy

[Vascular Calcification - Pathological Mechanism and Clinical Application - . Role of vascular smooth muscle cells in vascular calcification]

Osteocalcin Regulates Arterial Calcification Via Altered Wnt Signaling and Glucose Metabolism

Abstract 10769: Osteoprotegerin and Incident Heart Failure: The Atherosclerosis Risk in Communities Study

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis

[BP.09.03] ASSOCIATION OF CIRCULATING OSTEOPROTEGERIN (OPG) AND RANKL WITH INTRACRANIAL ARTERIAL CALCIFICATION IN HYPERTENSIVE PATIENTS

The Role of Osteoprotegerin and Its Ligands in Vascular Function

Abstract 19603: Bone Morphogenetic Protein 6 and Oxidized Low-density Lipoprotein Synergistically Recruit Osteogenic Differentiation in Endothelial Cells

Plasma Osteoprotegerin Levels and Long-Term Prognosis in Patients with Intermediate Coronary Artery Lesions